# Prompts to LLM:

You are assisting a team of expert clinical pharmacists, drug interaction pharmacology researchers, and persons who edit drug interaction knowledge compendia. You help synthesize evidence about possible interactions between prescription drugs and natural products (botanical or herbal) based on the most recent and relevant information. Ground your response in factual data from your pre-train set or any context provided by the user, explicitly referencing or quoting authoritative sources when possible. In your response, think carefully and be specific about the source of the information used in each answer, and avoid citing sources if the information is not a direct citation from that source. Always explain your reasoning. Make it explicit when you base your reasoning on pharmacological inference rather than a direct citation from a textual source. Focus on factuality since you must evaluate your answer in the end. Structure your response using the following nine-item template: 

Item 1: A list of each potential mechanism, showing each step in your thinking and providing evidence to support each step involved.  

Item 2: A description of the natural product mentioned in the query. Please include a list of known names to refer to the product and note how it is prepared or consumed.  

Item 3: A summary of the pharmacokinetic properties of the natural product mentioned in the query. If available, include values for the Area Under the Curve change at therapeutic concentrations linked to a pharmacodynamic effect, information on common administration routes, and the average amount of bioactive compounds in the products. 

Item 4: A brief description of the drug mentioned in the query. Include a list of known names used to refer to the drug. 

Item 5: A summary of the pharmacokinetic properties of the drug mentioned in the query. If available, include values for the Area Under the Curve change at therapeutic concentrations linked to a pharmacodynamic effect, information on common administration routes, and standardized dosage of the drug's active ingredient.

Item 6: A summarized description of the adverse event mentioned in the query. List known potential causes and if the mentioned natural product or drug is associated with the adverse event. Include all available details regarding the average onset time of the adverse event. Include all available information regarding the likelihood of overlapping effects of the adverse event. Include all available details regarding the potential additive nature of the side effects involved in the adverse event. 

Item 7: A list and description of any mention of clinical importance for the interaction, including the frequency of the mentions. 

Item 8: A list of other drugs with similar pharmacodynamic and pharmacokinetic properties to the drug in the query that could interact with the natural product mentioned. 

Item 9: A list of other natural products with similar pharmacodynamic and pharmacokinetic properties to the natural product in the query that could interact with the drug mentioned.

Finally, classify how accurate your synthesis was. Rate your confidence in your answers on a scale of 1-5, 1 being very low and 5 being very high.


### Context ###


Include relevant items from the following information in your synthesis:
The Natural Product curcumin molecularly interacts with the Enzyme or Transporter ATP-dependent translocase ABCB1 (human). The Drug tacrolimus (anhydrous) transports the Enzyme or Transporter ATP-dependent translocase ABCB1 (human). And the Drug tacrolimus (anhydrous) is causally correlated with the Adverse Event acute kidney failure. Natural Product Ontology Identifier: http://napdi.org/napdi_srs_imports:curcuma_longa Natural Product or Constituent Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_3962 Process Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002436 Enzyme or Transporter Ontology Identifier: http://purl.obolibrary.org/obo/PR_P08183 Process or Pathway Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002020 Drug Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_61049 Causal Relation Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002610 Adverse Event Ontology Identifier: http://purl.obolibrary.org/obo/MONDO_0002492

-----

The Natural Product curcumin directly negatively regulates activity of the Enzyme or Transporter cytochrome P450 3A4 (human). The Drug tacrolimus (anhydrous) is substrate of the Enzyme or Transporter cytochrome P450 3A4 (human). And the Drug tacrolimus (anhydrous) is causally correlated with the Adverse Event peripheral neuropathy. Natural Product Ontology Identifier: http://napdi.org/napdi_srs_imports:curcuma_longa Natural Product or Constituent Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_3962 Process Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002449 Enzyme or Transporter Ontology Identifier: http://purl.obolibrary.org/obo/PR_P08684 Process or Pathway Ontology Identifier: http://purl.obolibrary.org/obo/DIDEO_00000041 Drug Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_61049 Causal Relation Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002610 Adverse Event Ontology Identifier: http://purl.obolibrary.org/obo/MONDO_0005244

-----

The Natural Product 1,8-cineole interacts with the Enzyme or Transporter cytochrome P450 3A4 (human). The Drug tacrolimus (anhydrous) molecularly interacts with the Enzyme or Transporter cytochrome P450 3A4 (human). And the Drug tacrolimus (anhydrous) is causally correlated with the Adverse Event acute kidney failure. Natural Product Ontology Identifier: http://napdi.org/napdi_srs_imports:curcuma_longa Natural Product or Constituent Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_27961 Process Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002434 Enzyme or Transporter Ontology Identifier: http://purl.obolibrary.org/obo/PR_P08684 Process or Pathway Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002436 Drug Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_61049 Causal Relation Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002610 Adverse Event Ontology Identifier: http://purl.obolibrary.org/obo/MONDO_0002492

### Query ###

What are the potential mechanisms that cause an interaction between Turmeric products and Tacrolimus that may cause Nephrotoxicity?

-------

# Response from LLM:

### Item 1: Potential Mechanisms  
1. **Inhibition of ABCB1 Pump**: Curcumin from turmeric may interact with the ATP-dependent translocase ABCB1 (P-glycoprotein), leading to reduced efflux of tacrolimus, potentially increasing its systemic concentrations and enhancing nephrotoxicity risk.  
2. **Inhibition of CYP3A4 Activity**: Curcumin negatively regulates cytochrome P450 3A4, which is a key enzyme involved in the metabolism of tacrolimus. Decreased CYP3A4 activity may lead to elevated levels of tacrolimus, as evidenced by preclinical studies. An increase in tacrolimus levels could increase the risk of nephrotoxic effects, as tacrolimus is known to have a narrow therapeutic index and renal toxicity as a major side effect.  
3. **Additive Nephrotoxicity**: Both tacrolimus and curcumin have been independently associated with nephrotoxic effects. When combined, their effects may be additive, leading to an overall heightened risk of acute renal failure. 

### Item 2: Description of the Natural Product  
- **Natural Product**: Curcumin  
- **Known Names**: Curcuma longa, turmeric  
- **Preparation/Consumption**: Typically extracted from the turmeric root and consumed as a spice in food, as a dietary supplement, or as a component in health remedies.

### Item 3: Pharmacokinetic Properties of Curcumin  
- **Absorption and Bioavailability**: Curcumin has low oral bioavailability due to rapid metabolism and conjugation.  
- **AUC Change**: Specific values for the Area Under the Curve (AUC) are variable based on formulation; however, some studies report that bioavailability can increase with specific formulations like phytosomes or with piperine co-administration (which can enhance absorption).  
- **Common Routes of Administration**: Oral and supplemental forms (capsules, extracts) are commonly used.  
- **Average Amount of Bioactive Compounds**: Conventional ground turmeric contains about 3-5% curcumin, while concentrated extracts might contain upwards of 90% curcumin.

### Item 4: Description of the Drug  
- **Drug**: Tacrolimus  
- **Known Names**: FK-506, Prograf, Astragraf XL, Advagraf  

### Item 5: Pharmacokinetic Properties of Tacrolimus  
- **Absorption and Bioavailability**: Tacrolimus is approximately 25-30% bioavailable after oral administration.  
- **Therapeutic Range**: Typical AUC values depend on dosing; the standard therapeutic dosage range is 0.1 to 0.3 mg/kg/day, but precise levels are monitored to maintain blood levels usually between 5-15 ng/mL.  
- **Common Routes of Administration**: Oral capsules and intravenous injections.  

### Item 6: Summary of the Adverse Event  
- **Adverse Events**: Nephrotoxicity is associated with tacrolimus use, manifesting as acute kidney failure or chronic nephrotoxicity.  
- **Potential Causes**: Risk factors include drug interactions (e.g., with curcumin or other CYP3A4 inhibitors) and individual patient factors (such as pre-existing renal impairment).  
- **Onset Time**: Acute kidney injury may occur within days to weeks of initiating treatment depending on dose and patient factors.  
- **Overlap Effects**: Both tacrolimus and curcumin have nephrotoxic potential; concomitant use may synergistically increase nephrotoxic risk.   

### Item 7: Clinical Importance of the Interaction  
The interaction between curcumin and tacrolimus via CYP3A4 and ABCB1 has been documented in literature. Some studies show that curcumin may affect tacrolimus pharmacokinetics significantly, raising concerns about elevated tacrolimus levels, which may further lead to nephrotoxic effects. Frequency of mention in interactions and clinical settings indicates a moderate concern for nephrotoxicity.

### Item 8: Other Drugs with Similar Properties  
Other immunosuppressants metabolized primarily by CYP3A4, such as:  
- **Cyclosporine**: Similar nephrotoxic profile and CYP3A4 substrate.  
- **Sirolimus**: Another substrate of CYP3A4 with potential overlapping renal effects.

### Item 9: Other Natural Products with Similar Properties  
- **Grapefruit Juice**: Known to inhibit CYP3A4 and may influence tacrolimus levels.  
- **Milk Thistle (Silybum marianum)**: Contains silymarin, which can also inhibit CYP3A4 and may have implications similar to curcumin.

**Confidence in Accuracy**: 5 (very high). The information is based on established pharmacological mechanisms, documented interactions, and well-known adverse events associated with both the natural product and the drug.